Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
(Thomson Reuters ONE) -
WALTHAM, Mass., March 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of innovative therapies to treat unmet medical needs of central
nervous system (CNS) disorders, today announced the recent exercise of warrants
held by certain institutional stockholders in connection with a private
placement that took place in March 2015, as well as a purchase of common stock
completed on the open market by the chairman of Minerva's board of directors.
Since December 31, 2016, warrants with respect to a total of 1,621,073 shares
have been exercised by such stockholders at an exercise price of $5.772 per
share. As a result, the Company has received approximately $9.4 million in
proceeds since December 31, 2016. The warrants issued in connection with the
private placement expired on March 20, 2017.
Separately, 50,000 shares of Minerva common stock have been purchased by Marc
Beer, chairman of the board of directors of Minerva. These purchases took place
in multiple transactions at prices ranging from $7.65 to $8.45 and have been
reflected in a Form 4 filing with the Securities and Exchange Commission on
March 21, 2017.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of product
candidates to treat CNS diseases. Minerva's proprietary compounds include: MIN-
101, in clinical development for schizophrenia; MIN-117, in clinical development
for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical
development for insomnia and MDD; and MIN-301, in pre-clinical development for
Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global
Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
Datum: 21.03.2017 - 21:10 Uhr
Sprache: Deutsch
News-ID 531659
Anzahl Zeichen: 2669
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 136 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
